15.80
price up icon0.60%   0.095
after-market After Hours: 15.90 0.10 +0.63%
loading
Arrowhead Pharmaceuticals Inc stock is traded at $15.80, with a volume of 1.20M. It is up +0.60% in the last 24 hours and up +0.00% over the past month. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$15.71
Open:
$15.9278
24h Volume:
1.20M
Relative Volume:
0.68
Market Cap:
$2.18B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-11.37
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-2.83%
1M Performance:
+0.00%
6M Performance:
-20.52%
1Y Performance:
-44.68%
1-Day Range:
Value
$15.58
$16.05
1-Week Range:
Value
$15.51
$16.69
52-Week Range:
Value
$9.57
$28.72

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Name
Arrowhead Pharmaceuticals Inc
Name
Phone
626-696-4702
Name
Address
177 E COLORADO BLVD, PASADENA, CA
Name
Employee
609
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
ARWR's Discussions on Twitter

Compare ARWR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
15.80 2.17B 181.74M -143.97M 9.60M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-24 Initiated Goldman Neutral
Dec-04-23 Initiated BofA Securities Buy
Sep-19-23 Initiated Citigroup Neutral
Jul-21-23 Initiated TD Cowen Outperform
May-12-23 Downgrade SVB Securities Outperform → Market Perform
Apr-26-23 Initiated SMBC Nikko Outperform
Apr-12-23 Upgrade SVB Securities Market Perform → Outperform
Mar-21-23 Initiated Bernstein Mkt Perform
Sep-09-22 Initiated Morgan Stanley Equal-Weight
May-11-22 Upgrade Robert W. Baird Neutral → Outperform
Jan-19-22 Resumed Goldman Buy
Aug-06-21 Reiterated Chardan Capital Markets Buy
Jun-04-21 Resumed Robert W. Baird Neutral
Feb-05-21 Reiterated H.C. Wainwright Buy
Dec-21-20 Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20 Initiated UBS Buy
Nov-19-20 Initiated Citigroup Buy
May-13-20 Initiated RBC Capital Mkts Outperform
May-08-20 Upgrade Oppenheimer Perform → Outperform
Apr-15-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-24-20 Upgrade SVB Leerink Underperform → Mkt Perform
Mar-17-20 Initiated Goldman Neutral
Jan-21-20 Initiated SVB Leerink Underperform
Dec-13-19 Initiated Oppenheimer Perform
Nov-29-19 Reiterated Chardan Capital Markets Buy
Nov-27-19 Reiterated B. Riley FBR Buy
Nov-25-19 Upgrade Robert W. Baird Neutral → Outperform
Oct-24-19 Downgrade Robert W. Baird Outperform → Neutral
Oct-22-19 Reiterated Chardan Capital Markets Buy
Oct-03-19 Initiated Robert W. Baird Outperform
Sep-07-18 Upgrade B. Riley FBR Neutral → Buy
Sep-06-18 Reiterated Chardan Capital Markets Buy
Aug-08-18 Reiterated Cantor Fitzgerald Overweight
Jul-02-18 Reiterated Chardan Capital Markets Buy
View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

pulisher
Jul 31, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

11 Best Future Stocks to Buy Now - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Why Arrowhead Pharmaceuticals Inc. stock attracts strong analyst attentionConfirmed Setup With Expert Accuracy Supported - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Competitive Positioning of Arrowhead Pharmaceuticals Inc.: Is It Leading or LaggingStock Market Entry Timing Signals Revealed - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN

Jul 30, 2025
pulisher
Jul 29, 2025

Arrowhead Pharmaceuticals Inc. Inches Above Key Support — Safe to HoldTarget Return Focused Trade Insights Shared - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 29, 2025

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - BioSpace

Jul 29, 2025
pulisher
Jul 28, 2025

Sarepta Owes $100 Million to Partner as Financial Pressure Grows - Bloomberg

Jul 28, 2025
pulisher
Jul 28, 2025

Arrowhead, Sarepta Advance on Pact - Baystreet.ca

Jul 28, 2025
pulisher
Jul 28, 2025

Arrowhead (ARWR) Secures $100 Million Milestone from Sarepta - GuruFocus

Jul 28, 2025
pulisher
Jul 28, 2025

Arrowhead (ARWR) Secures $100M Milestone from Sarepta in Clinica - GuruFocus

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy Arrowhead Pharmaceuticals Inc. stockInvest with confidence backed by data - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Arrowhead Pharmaceuticals Inc. stock compared to the marketRapid wealth multiplication - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Arrowhead Pharmaceuticals Inc. stock overvalued or undervaluedMarket-leading capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Arrowhead Shares Bumpy After Partner Troubles - Los Angeles Business Journal

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Arrowhead Pharmaceuticals Inc. company’s balance sheetHigh-return market picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Arrowhead Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveTop Analyst Picks - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Is Arrowhead Pharmaceuticals Inc. a growth stock or a value stockUnlock daily market insights for better decisions - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Arrowhead Pharmaceuticals Inc. stock performs during market volatilityMinimized Risk Maximum Return - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What are Arrowhead Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving market trends - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Arrowhead Pharmaceuticals Inc.High-margin investment plays - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Arrowhead Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is Arrowhead Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid capital gains with smart investing - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Arrowhead Pharmaceuticals Inc. in the next 12 monthsUnlock the power of real-time market data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is Arrowhead Pharmaceuticals Inc. a good long term investmentFree Consultation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)July 24, 2025 - BioSpace

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Arrowhead Pharmaceuticals Inc. stockExplosive returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ARWR Stock News - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 24, 2025

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - BioSpace

Jul 24, 2025
pulisher
Jul 23, 2025

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks - Reuters

Jul 23, 2025
pulisher
Jul 23, 2025

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement By Stocktwits - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Arrowhead Pharmaceuticals (ARWR) Awaits Sarepta Payments Amid Re - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

Arrowhead Stays Confident In Sarepta’s Commitment Despite Restructuring - Finimize

Jul 23, 2025
pulisher
Jul 23, 2025

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

Sarepta’s licensing partner Arrowhead expects near-term payments despite setbacks - whbl.com

Jul 23, 2025
pulisher
Jul 23, 2025

Arrowhead expects Sarepta to meet deal terms (ARWR:NASDAQ) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPhenomenal capital gains - jammulinksnews.com

Jul 23, 2025

Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):